Bone-targeted delivery of nanodiamond-based drug carriers conjugated with alendronate for potential osteoporosis treatment

This paper describes the design of alendronate-conjugated nanodiamonds (Alen-NDs) and evaluation of their feasibility for bone-targeted delivery. Alen-NDs exhibited a high affinity to hydroxyapatite (HAp, the mineral component of bone) due to the presence of Alen. Unlike NDs (without Alen), Alen-NDs...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2016-06, Vol.232, p.152-160
Main Authors: Ryu, Tae-Kyung, Kang, Rae-Hyoung, Jeong, Ki-Young, Jun, Dae-Ryong, Koh, Jung-Min, Kim, Doyun, Bae, Soo Kyung, Choi, Sung-Wook
Format: Article
Language:English
Subjects:
Alendronate
Alendronate - administration & dosage
Alendronate - chemistry
Alendronate - pharmacokinetics
Alkaline Phosphatase - metabolism
Animals
Bone and Bones - metabolism
Bone Density Conservation Agents - administration & dosage
Bone Density Conservation Agents - chemistry
Bone Density Conservation Agents - pharmacokinetics
Bone targeting
Cell Line
Drug Carriers - administration & dosage
Drug Carriers - chemistry
Drug Carriers - pharmacokinetics
Durapatite - chemistry
Female
Hep G2 Cells
Humans
Mice, Inbred BALB C
Mice, Nude
Nanodiamond
Nanodiamonds - administration & dosage
Nanodiamonds - chemistry
Osteoporosis
Osteoporosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This paper describes the design of alendronate-conjugated nanodiamonds (Alen-NDs) and evaluation of their feasibility for bone-targeted delivery. Alen-NDs exhibited a high affinity to hydroxyapatite (HAp, the mineral component of bone) due to the presence of Alen. Unlike NDs (without Alen), Alen-NDs were preferentially taken up by MC3T3-E1 osteoblast-like cells, compared to NIH3T3 and HepG2 cells, suggesting their cellular specificity. In addition, NDs itself increased ALP activity of MC3T3-E1 cells, compared to control group (osteogenic medium) and Alen-NDs exhibited more enhanced ALP activity. In addition, an in vivo study revealed that Alen-NDs effectively accumulated in bone tissues after intravenous tail vein injection. These results confirm the superior properties of Alen-NDs with advantages of high HAp affinity, specific uptake for MC3T3-E1 cells, positive synergistic effect for ALP activity, and in vivo bone targeting ability. The Alen-NDs can potentially be employed for osteoporosis treatment by delivering both NDs and Alen to bone tissue. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2016.04.025